Mycobacterium abscessus

Microbion Corporation Announces Poster Highlighting Pravibismane Activity Against Common Cystic Fibrosis Pulmonary Pathogens to be Presented at the North American Cystic Fibrosis Conference 2022

Retrieved on: 
Thursday, November 3, 2022
Doctor of Philosophy, Company, NTM, Mycobacterium abscessus, Growth, Cystic Fibrosis Foundation, Cystic fibrosis, Multimedia, Infection, Wellcome Trust, CF, Federal Ministry of Health (Germany), Mycobacterium, FDA, Investor, Safety, Seattle Children's, Department, Conference, Poster, Education, QIDP, Staphylococcus aureus, Orphan drug, Intention, Respiratory tract, Stenotrophomonas maltophilia, Hospital, Burkholderia cepacia complex, US, ATP, Pseudomonas aeruginosa, Assistant, Degenerative disease, Cooperative, Chronic lung disease, Urinary tract infection, NIH, Federal Ministry of Education and Research (Germany), Patient, MD, Acinetobacter baumannii, United States Department of Defense, Pharmaceutical industry, BC, Research

BOZEMAN, MT and VANCOUVER, BC, Nov. 3, 2022 /PRNewswire/ - Microbion Corporation today announced that the company will present a poster at the North American Cystic Fibrosis Conference, November 3 5, in Philadelphia, PA highlighting the activity of pravibismane against bacterial pathogens associated with lung infection in people with cystic fibrosis (CF).

Key Points: 
  • BOZEMAN, MT and VANCOUVER, BC, Nov. 3, 2022 /PRNewswire/ - Microbion Corporation today announced that the company will present a poster at the North American Cystic Fibrosis Conference, November 3 5, in Philadelphia, PA highlighting the activity of pravibismane against bacterial pathogens associated with lung infection in people with cystic fibrosis (CF).
  • Title:Investigating the activity of pravibismane against bacterial isolates common in cystic fibrosis pulmonary infections (Poster No.
  • The presence of pulmonary surfactant did not have an impact on pravibismane activity.
  • Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants.

Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs

Retrieved on: 
Monday, October 3, 2022
Urinary tract infection, FSE, Cystic fibrosis, GLOBE, Pyelonephritis, Recce, UTI, Infection, Urine, Streptococcus, Degenerative disease, RCE, Virus, Synthetic, FDA, ASX, GAIN, Gram-negative bacteria, Burn, Male, Mycobacterium abscessus, Bacteria, DFU, Sepsis, Safety, Streptococcus pneumoniae, Time-invariant system, Sydney, Pew, Patient, Kidney, Diabetic foot ulcer, Woman, Helicobacter pylori, Company, Pharmaceutical industry, Antibiotics, Vaccine

SYDNEY Australia, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing new classes of synthetic anti-infectives, is pleased to provide an updated timeline on its clinical programs with several significant data read-outs in 2022 and 2023.

Key Points: 
  • We have therefore established an ambitious development plan, aiming to get new anti-infective therapies into market as expediently possible.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.
  • Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

Retrieved on: 
Monday, September 26, 2022
Risk, Medical University of South Carolina, Investor, Degenerative disease, Anthrax, Development, Infection, Journal, International Work Group for Indigenous Affairs, Q&A, Mycobacterium abscessus, LLC, BARDA, Gram, Tuberculosis, Biomedical Advanced Research and Development Authority, Critical care, Antimycobacterial, Office of Inspector General, U.S. Department of Health and Human Services, U.S. Securities and Exchange Commission, Government, Patient, ABSSSI, U.S. Department of Defense Strategy for Operating in Cyberspace, Bronchiectasis, Pediatrics, Tetracycline, MAC, Public health, Annual report, Bacteria, Nasdaq, Radboud University Medical Center, Diagnosis, Bronchopneumonia, Medical school, Research, Security (finance), Cystic fibrosis, GLOBE, Medicine, Acne, NTM, Mycobacterium, Pharmaceutical industry, Medical device, Vaccine

Dr. van Ingen will discuss the global epidemiology and NTM treatment challenges.

Key Points: 
  • Dr. van Ingen will discuss the global epidemiology and NTM treatment challenges.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
  • Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
  • We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million

Retrieved on: 
Wednesday, August 3, 2022
Annual report, Tablet, Regulation Fair Disclosure, Degenerative disease, Treatment, Nasdaq, Investor relations, Family medicine, Journal, Acne, SG, Growth, Skin, Tetracycline, Gram, Risk, U.S. Securities and Exchange Commission, ABSSSI, Development, FDA, Bacteria, Pneumonia, GLOBE, Income, Fast Track, Physician, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Mycobacterium abscessus, Patient, Disclosure, LinkedIn, Twitter, LLC, Bronchopneumonia, Public health, Second, Security (finance), Post-exposure prophylaxis, Mycobacterium avium complex, Company, Anthrax, Biomedical Advanced Research and Development Authority, NTM, Government, Research, R, ID, BARDA, Regulation, Office of Inspector General, U.S. Department of Health and Human Services, SEC, Video game, Pharmaceutical industry, Vaccine

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) --  Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the quarter ended June 30, 2022.

Key Points: 
  • Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021
    BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the quarter ended June30, 2022.
  • Total revenue for the second quarter of 2022 was $29.6 million compared to $19.6 million for the same period in the prior year when excluding the first procurement of NUZYRA under the BARDA contract of $37.9 million.
  • Revenue earned in the second quarter of 2022 was comprised of $25.1 million in net U.S. sales from the NUZYRA core commercial business, a 68% increase from $14.9 million for the same period in the prior year, $4.0 million in revenue earned under the BARDA contract, and $0.6 million in royalty revenue.
  • Research and development (R&D) expenses were $7.6 million for the second quarter of 2022, compared to $6.5 million for the same period in the prior year.

Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB)

Retrieved on: 
Tuesday, June 21, 2022
Biomedical Advanced Research and Development Authority, Review, Fever, FDA, Fatigue, Cough, Public health, Tetracycline, Risk, Degenerative disease, Safety, Annual report, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Government, BARDA, IV, Security (finance), U.S. Securities and Exchange Commission, Anthrax, LLC, MAB, Mycobacterium abscessus, ABSSSI, LinkedIn, Fast Track, Disease, Mycobacterium avium complex, Bacteria, Nasdaq, Development, Gram, Twitter, MAC, Food, Patient, Bronchopneumonia, Acne, Urinary tract infection, Office of Inspector General, U.S. Department of Health and Human Services, NTM, GLOBE, Pharmaceutical industry, Vaccine, Public relations

BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced the U.S. Food and Drug Administration has granted Fast Track designation for the oral and IV formulations of the company’s novel, broad-spectrum antibiotic NUZYRA® (omadacycline) for the treatment of pulmonary Nontuberculous Mycobacterial (NTM) disease caused by both Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB). These NTM indications are rare diseases for which new therapies are desperately needed. FDA granted NUZYRA orphan drug designation for these infections in August 2021.

Key Points: 
  • FDA granted NUZYRA orphan drug designation for these infections in August 2021.
  • In the United States alone, currently NTM pulmonary infections caused by MAB affect approximately 11,500 patients while an estimated 100,000 cases are caused by MAC.
  • Treatment can often be life-long in duration and complicated by long-term tolerability challenges and multiple adverse events.
  • As noted above, Paratek is conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease caused by MAB.

Microbion Corporation Announces Data Highlighting In Vitro Activity of Pravibismane in NTM, including Activity Against NTM Causing Intracellular Infections, to be Presented at the Colorado Mycobacteria Conference 2022

Retrieved on: 
Wednesday, June 1, 2022
Company, Conference, MDR, NIH, IND, Mycobacterium avium-intracellulare infection, Biofilm, Chronic lung disease, Amikacin, NTM, Drug development, MDT, Mycobacterium abscessus, THP-1 cell line, Breathe Me, Hemoptysis, Depression, Fever, QIDP, Assistant, Federal Ministry of Education and Research (Germany), ATP, Colorado State University, Intention, Mycobacterium, United States Department of Defense, Malaise, Toxicity, Wellcome Trust, Cough, Patient, Cystic Fibrosis Foundation, Incidence, Department, Investor, Cooperative, Pseudomonas aeruginosa, Education, US, Program, JO, Fatigue, Rifampicin, FDA, Growth, Federal Ministry of Health (Germany), Respiratory tract, MIC, MRSA, Infection, Orphan drug, Safety, Medical device, Pharmaceutical industry, Research

Pravibismane demonstrated an MIC of 0.3125 g/mL and 0.625 g/mL and against M. avium and M. abscessus intracellular infection in THP-1 cells, respectively.

Key Points: 
  • Pravibismane demonstrated an MIC of 0.3125 g/mL and 0.625 g/mL and against M. avium and M. abscessus intracellular infection in THP-1 cells, respectively.
  • As low as 2.5 g/mL pravibismane reduces intracellular M. avium 2285R (MDR) and M. abscessus 1153 (MDR) burden, superior to 20 g/mL rifampin and amikacin control drugs, respectively.
  • With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism.
  • Pravibismane exhibits broad-spectrum, potent in vitro activity against chronic respiratory infection-relevant pathogens and their biofilms including NTM, multidrug resistant P. aeruginosa and MRSA.

Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million

Retrieved on: 
Wednesday, May 4, 2022
Development, Disclosure, Bronchopneumonia, Risk, Annual report, Bioterrorism, Post-exposure prophylaxis, SEC, Expansion, Anthrax, Twitter, Company, Regulation, Government, Gram, U.S. Securities and Exchange Commission, Acne, Program, SG, LinkedIn, Tetracycline, Disease, Biomedical Advanced Research and Development Authority, Medicare, Insurance, Omicron, SNS, Physician, Research, ABSSSI, Security (finance), Mycobacterium, MAC, R, Public health, Bacteria, Growth, Exercise, Mycobacterium abscessus, BARDA, Regulation Fair Disclosure, Nasdaq, GLOBE, LLC, Tablet, U.S. Department of Defense Strategy for Operating in Cyberspace, Degenerative disease, NTM, Office of Inspector General, U.S. Department of Health and Human Services, Investor relations, Patient, ID, Motor vehicle, Pharmaceutical industry, Vaccine, Video game

BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022.

Key Points: 
  • Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021
    BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March31, 2022.
  • Total revenue was $24.9 million for the first quarter of 2022, a 51% increase from $16.4 million for the same period in the prior year.
  • Total revenue for the first quarter of 2022 was comprised of the following:
    NUZYRA generated net U.S. sales of $19.9 million, a 51% increase from $13.2 million for the same period in the prior year.
  • Research and development (R&D) expenses were $7.5 million for the first quarter of 2022, compared to $5.5 million for same period in the prior year.

Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

Retrieved on: 
Tuesday, April 26, 2022
Anthrax, Government, NTM, Tetracycline, Degenerative disease, Bioterrorism, ABSSSI, LLC, U.S. Securities and Exchange Commission, Security (finance), Risk, Annual report, Bacteria, Mycobacterium abscessus, GLOBE, Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, Bronchopneumonia, Bacillus anthracis, Development, Nasdaq, Gram, ID, Public health, Plague, Acne, BARDA, U.S. Department of Defense Strategy for Operating in Cyberspace, Pharmaceutical industry, Vaccine

ET to report its financial results for the first quarter of 2022.

Key Points: 
  • ET to report its financial results for the first quarter of 2022.
  • Domestic investors wishing to participate in the call should dial: 877-300-8521 and international investors should dial: +1-412-317-6026.
  • Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.
  • Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Felix Biotechnology Awarded Competitive Grant from the National Science Foundation to Power Phage Engineering Platform

Retrieved on: 
Thursday, September 2, 2021
Infection, Partnership, SBIR, Thought, Pseudomonas aeruginosa, SAN, Science, Solution, ML, Engineering, Mycobacterium abscessus, Division, Bacteria, NSF, Department of Industry, Innovation, Climate Change, Science, Research and Tertiary Education, Doctor of Philosophy, Virus, National Science Foundation, Phage therapy, Technology, Health, Pharmaceutical industry

Phage have key benefits relative to small molecule antibiotics, but there are several hurdles to turning phage into a true biotherapeutic.

Key Points: 
  • Phage have key benefits relative to small molecule antibiotics, but there are several hurdles to turning phage into a true biotherapeutic.
  • These rich datasets power our ML and genetic engineering tools, creating a platform for tuning phage specificity and producing phage products targeting dangerous human pathogens, like P. aeruginosa and Mycobacterium abscessus," said Felix Biotechnology co-founder and principal investigator on the grant, Natalie Ma, PhD.
  • "Felix is tackling the most challenging technical hurdles limiting the broad application of phage therapy to the clinic.
  • For more on Felix Biotechnology, please visit: https://www.felixbt.com/
    For more on the National Science Foundation's Small Business Programs, please visit: https://seedfund.nsf.gov/

Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)

Retrieved on: 
Wednesday, June 16, 2021
Acid-fast bacilli, Mycobacterium abscessus, Health, Medical specialties, Microbiology, Lung disorders, Nontuberculous mycobacteria

Pulmonary infections caused by MABc, an orphan disease with no FDA-approved antibiotic therapies, affects approximately 11,500 patients in the U.S.

Key Points: 
  • Pulmonary infections caused by MABc, an orphan disease with no FDA-approved antibiotic therapies, affects approximately 11,500 patients in the U.S.
  • Patients with pulmonary disease caused by M. abscessus have a myriad of symptoms including severe fatigue, fever, cough and shortness of breath.
  • The Phase 2b study is a placebo-controlled, randomized monotherapy study of M. abscessus pulmonary disease in patients in the early treatment phase who are not receiving other treatments.
  • Due to the small numbers of patients with this rare disease, Paratek expects the study will take about two years to complete enrollment.